Emerging Technologies (11)

Alexander Richter, executive director and head of the SciTech Innovation Hub at SciTech Scity, shares how the organization identifies, pilots and scales healthcare innovations through close collaboration with public- and private-sector partners.

Dave Rosa, CEO of NeuroOne, outlines the company's minimally invasive electrode technology designed to improve neurological care for patients with motor issues and pain, using thin-film, flexible electrodes implanted on the brain.

Dr. Mark Zhang, acting assistant under secretary for health at the U.S. Department of Veterans Affairs, discusses the VA Puget Sound Health Care System's X_Labs and 3D-printed bone grafts.

Connor Glass, founder and CEO of Phantom Neuro, discusses the company's muscle machine interface that records electrical activity from one's body, decodes it and uses it to allow them to control a robotic prosthetic limb using their mind.

Julien Payen, CEO and cofounder of Lattice Medical, a French American company specializing in tissue engineering, discusses Mattice—a 3D-printed scaffold, a resorbable breast implant designed for regrowing one’s own breast tissue.

Anne Osdoit, CEO of Moon Surgical, discusses the company’s surgical robot, Maestro, designed for laparoscopic soft-tissue procedures, which provides surgeons with an extra set of hands so they can focus more fully on the operation itself.

Nissan Elimelech, founder of Augmedics, explains how the company’s augmented reality surgical technology allows surgeons see a virtual spine overlay directly on a patient during an operation, eliminating the need to look at a monitor.

Paul Grand, CEO of MedTech Innovator, shares how the accelerator evaluates startups for innovation and scalability and connects them with industry partners to accelerate growth and ultimately bring their offerings to market effectively.

Molly Gibson, president of future science at Lila Sciences, discusses the company's superintelligence platform to advance scientific research, AI technology's promise in curing diseases and the risks the company is watching out for.

Morgan Cheatham, partner and head of healthcare and life sciences at Breyer Capital, highlights the venture capital firm's strategy for funding emerging technologies and its rigorous evaluation of a technology's potential for maturation.

Precision Neuroscience kicks off the Emerging Technologies series, with Jayme Strauss, the company’s chief clinical and commercial officer, discussing the Layer 7 cortical interface, a minimally invasive brain-computer interface.